Progression of CAR-T trials in China
Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, gives an overview of the current CAR T-cell trial activities in China. Prof. Wang highlights the progression of the bispecific CAR-T targeting CD19 and CD22 and the BCMA and CD19 bispecific CAR-T, both manufactured in the FasT CAR-T platform. A novel TCR-based extracellular complex, STAR (synthetic TCR and antigen receptor), is being investigated in China. STAR T-cells may have improved persistence after infusion. Lastly, Prof. Wang discusses a new CD7-CAR T-cell product against T-cell malignancies. This interview took place during the 3rd European CAR T-cell Meeting.
Видео Progression of CAR-T trials in China канала VJRegenMed
Видео Progression of CAR-T trials in China канала VJRegenMed
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![CAR-T trials to watch in China](https://i.ytimg.com/vi/g-dN3U2Ht9U/default.jpg)
![Exploring the potential role of CD7-targeting CAR-T cells in T-ALL](https://i.ytimg.com/vi/YlMw43TyJHQ/default.jpg)
![Current developments in cell therapies for solid tumors](https://i.ytimg.com/vi/QITTCJh9Fvo/default.jpg)
![Tabelecleucel in EBV-associated PTLD](https://i.ytimg.com/vi/8JcXIlfI-q8/default.jpg)
![Challenges in decentralized manufacturing systems](https://i.ytimg.com/vi/T3PBj8gYXH8/default.jpg)
![PiggyBac Transposon-generated CAR T-cells in solid tumors](https://i.ytimg.com/vi/UZ1FNxol_EM/default.jpg)
![Nerve regeneration with polyhydroxyalkanoate-based conduits](https://i.ytimg.com/vi/5Iv5tFCWmt0/default.jpg)
![LUMEVOQ gene therapy for LHON](https://i.ytimg.com/vi/ZICV7g0pPno/default.jpg)
![Harnessing lipid-specific TCRs to target CD1c-expressing leukemia](https://i.ytimg.com/vi/WH1CmN9pOtw/default.jpg)
![EV-based therapies for myocardial infarction](https://i.ytimg.com/vi/xmCwbtvybxo/default.jpg)
![Plasmacytoid dendritic cell-based cancer vaccines](https://i.ytimg.com/vi/iOzC5GkNcxQ/default.jpg)
![Paige Bischoff, Senior VP, Public Affairs, Alliance for Regenerative Medicine](https://i.ytimg.com/vi/x34AXUWTAZI/default.jpg)
![The changing landscape of hospital-based cell and gene therapy manufacturing](https://i.ytimg.com/vi/ewPHBOWF2ME/default.jpg)
![Increasing manufacturing capabilities for gene therapies](https://i.ytimg.com/vi/cdzjk2TvcIQ/default.jpg)
![Developing gene therapies for GJB2 gene related hearing loss](https://i.ytimg.com/vi/ZkRtcwnfNvs/default.jpg)
![Addressing supply chain issues in clinical trials](https://i.ytimg.com/vi/Ha3wm2ZfevE/default.jpg)
![IL-1Ra gene therapy for knee OA: interim Phase I results](https://i.ytimg.com/vi/sGl5q1-EvUM/default.jpg)
![Enhancing AAV gene therapy in children with inborn errors of metabolism](https://i.ytimg.com/vi/XJEA-vlmwIM/default.jpg)
![SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS](https://i.ytimg.com/vi/adXUZr--4ok/default.jpg)
![The past, present and future of AAV vectors](https://i.ytimg.com/vi/18UhN4mrjZU/default.jpg)